Ergomed (ERGO)

 

ERGO Share PerformanceMore

52 week high216.90 28/02/17
52 week low118.00 14/10/16
52 week change 58.00 (48.33%)
4 week volume602,812 27/08/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Ergomed net service revenues up 53%

Ergomed's first half net service revenues rose by 53% to 19.5m and total revenues were up 31% at 22.9m. Gross profit rose b...

Interim Results

RNS Number: 9653Q Ergomed plc 18 September 2017 PRESS RELEASE Unaudited Interim results for the six months ended 30 June 2017 Strong first half financial performance - net service revenues up 53 % and gross profit up 42% Haemostatix programmes significantly advanced, PeproStat Phase IIb study ahead of schedule London, UK - 18 September 2017: Ergom...

CEL-SCI Corporation issues restricted shares

RNS Number: 5035O Ergomed plc 21 August 2017 PRESS RELEASE FOR IMMEDIATE RELEASE CEL-SCI Corporation issues restricted shares to Ergomed for partial settlement of receivable London, UK - 21 August 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company dedicated to the provision of specialised services to the pharmaceutical indu...

Ergomed's partner to resume Phase 3 study of Multikine

Ergomed said it has noted that its co-development partner CEL-SCI has confirmed the US Food and Drug Administration ...

FDA removal of hold on Ph3 trial with Multikine

RNS Number: 9319N Ergomed plc 14 August 2017 PRESS RELEASE Ergomed notes announcement by co-development partner, CEL-SCI, of FDA removal of clinical hold on Phase 3 clinical trial with Multikine in head and neck cancer London, UK - 14 August 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a specialised pharmaceutical services and dr...

Ergomed schedules interim results

Ergomed, a specialised pharmaceutical services and drug development company, will announce its results for the six mont...

Notice of Results

RNS Number: 8501N Ergomed plc 14 August 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Notice of interim results London, UK - 14 August 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a specialised pharmaceutical services and drug development company, will announce its Interim Results for the six months ended 30 June 2017 on Monday...

Ergomed completes study recruitment ahead of schedule

Ergomed has completed recruitment for its phase IIb proof-of-concept study for PeproStat, its innovative new coagulant, o...

Fundamental DataMore

P/E ratio136.923
EPS1.3
Dividend yield0 %

Equity Research (ERGO)

equity development
Ergomed plc
21/09/2017
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. Performance in H1 was in line with expectations as...
equity development
Ergomed Plc
08/05/2017
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. Aeterna Zentaris, a co-development partner of...
equity development
Ergomed Plc
12/04/2017
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. 2016 perfectly highlighted the strengths of the...

Latest discussion posts More

  • great news,,,,boom

    buy
    14-Aug-2017
    one4all
  • Results webinar

    If you would like to hear management present the preliminary results for the year ended 31 December 2016 for Ergomed we will be hosting a webinar on Wednesday 29th March at ...
    22-Mar-2017
    equity_dev
  • See management present

    If you would like to hear Stephen Stamp, Chief Finance Officer, present on behalf of Ergomed he will be appearing at our next investor forum on the evening of Wednesday 25th of ...
    17-Jan-2017
    equity_dev

Users' HoldingsMore

Users who hold Ergomed also hold..
TRITAX BIG BOX27%
INSPIRED ENERGY27%
ID:ISIN:VGG9828A119427%
MAXCYTE (DI)18%
ROSE PETROL.18%

Codes & Symbols

ISINGB00BN7ZCY67
SymbolsERGO, LSE:ERGO, ERGO.L, ERGO:LN, LON:ERGO, XLON:ERGO